Vaccinex, Inc.

FOR IMMEDIATE RELEASE

VACCINEX, INC TO PRESENT AT ANTIBODY WORLD SUMMIT

ROCHESTER, NY - Vaccinex, Inc., a leading antibody discovery and development company, announced today that the firm has again been selected this year to present at the Antibody World Summit in San Francisco from June 12-14, 2006. In addition, Vaccinex's President and CEO, Dr. Maurice Zauderer, will be co-chairman of a specialized session entitled "Antibody Discovery and Development."

In regards to the conference, Dr. Zauderer commented, "We are very pleased to be participating in the Antibody World Summit again this year, which marks our fifth year as a presenting company. As a major conference of the antibody industry, we have found this to be an excellent opportunity to highlight Vaccinex's capabilities and achievements in antibody discovery and development to scientists, commercial partners and other industry participants."

Vaccinex is a privately held biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Using its proprietary vaccinia vector technology, Vaccinex has developed a unique library-based discovery platform capable of identifying novel antigens and of selecting fully human monoclonal antibodies against disease targets. This technology can also be used to fully humanize mouse and other non-human antibodies. Utilizing its proprietary ActivMAb technology, the company has discovered four fully human, therapeutic antibody products that are entering pre-clinical development in 2006. The firm is headquartered in Rochester, NY and currently has 48 employees.

CONTACTS:

Raymond E. Watkins, Vice President of Operations, 585.271.2700 (x-105) - rwatkins@vaccinex.com

Back to News Archive


About Us Executive Team Board of Directors Scientific/ Clinical Advisors Business Strategy Collabora- tions Antibody Technology Overview Membrane Antibody Expression and Selection Secreted IgG Antibody Selection Antibody Animation Development Strategy Development Pipeline


	FOR IMMEDIATE RELEASE VACCINEX, INC TO PRESENT AT ANTIBODY WORLD SUMMIT ROCHESTER, NY - Vaccinex, Inc., a leading antibody discovery and development company, announced today that the firm has again been selected this year to present at the Antibody World Summit in San Francisco from June 12-14, 2006. In addition, Vaccinex's President and CEO, Dr. Maurice Zauderer, will be co-chairman of a specialized session entitled "Antibody Discovery and Development." In regards to the conference, Dr. Zauderer commented, "We are very pleased to be participating in the Antibody World Summit again this year, which marks our fifth year as a presenting company. As a major conference of the antibody industry, we have found this to be an excellent opportunity to highlight Vaccinex's capabilities and achievements in antibody discovery and development to scientists, commercial partners and other industry participants." Vaccinex is a privately held biotechnology company engaged in the discovery and development of novel therapeutic antibodies. Using its proprietary vaccinia vector technology, Vaccinex has developed a unique library-based discovery platform capable of identifying novel antigens and of selecting fully human monoclonal antibodies against disease targets. This technology can also be used to fully humanize mouse and other non-human antibodies. Utilizing its proprietary ActivMAb technology, the company has discovered four fully human, therapeutic antibody products that are entering pre-clinical development in 2006. The firm is headquartered in Rochester, NY and currently has 48 employees. CONTACTS: Raymond E. Watkins, Vice President of Operations, 585.271.2700 (x-105) - rwatkins@vaccinex.com Back to News Archive Copyright © 2008 Vaccinex, Inc.